Page 3 - Demo

CONTENTS
NEXT STEPS IN CANCER IMMUNOTHERAPY
AGENDA
6/20 DAY1
............. 04
............. 04 ............. 04 ............. 04
............. 04 ............. 04 ............. 04 ............. 04
............. 04 ............. 04 ............. 04
............. 04 ............. 04 ............. 04
SESSION
MODERATOR SPEAKER TOPIC
SPEAKER TOPIC SPEAKER TOPIC
SESSION
MODERATOR SPEAKER TOPIC
SESSION
MODERATOR SPEAKER TOPIC
Virus Driven Cancers
張義芳|周獻堂|楊慕華
王研人-馬偕紀念醫院
• Merkel Cell Carcinoma (MCC): Viral Antigen as Tumor Rejection Antigens
• Final Results from a Phase 2 Study Using Off-the-shelf Activated Natural Killer Cells in Combination with
N-803, an IL-15 Superagonist, in Patients with Metastatic MCC
陳榮隆-和信治癌中心醫院
• EBV and Cancers 連銘渝-中國醫藥大學附設醫院
• HPV and Head and Neck Cancers
NK Cells: From Basic Science to Clinical Application
徐祖安
張順浪-基亞生物科技公司
• Harnessing Innate Immunity in Cancer
• Enhanced presence of a myeloid-like NK cell subpopulation is associated with MHC class I-deficient tumor escape
High Impact Clinical Trials in NSCLC
張文震
周百謙-臺北醫學大學附設醫院
• IMpower110: Interim overall survival analysis of a Phase
III study of atezolizumab monotherapy vs platinum-based chemotherapy as first-line treatment in PD-L1–selected NSCLC
• A phase II study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC: Updated analysis
4